Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy
Open accessAbstract
// Bo Zhang 1, * , Wei Shi 1, * , Ting Jiang 1 , Lanting Wang 2, 3 , Heng Mei 1, 4 , Heng Lu 2 , Yu Hu 1, 4 , Zhiqing Pang 2 1 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, PR China 2 Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, China 3 School of Medicine, Fudan University, Shanghai, China 4 Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, China * These authors have contributed equally to this work Correspondence to: Yu Hu, email: dr_huyu@126.com Zhiqing Pang, email: zqpang@fudan.edu.cn Keywords: tumor microenvironment, imatinib mesylate, nanoparticles, micelles, nanomedicine size Received: April 02, 2016 Accepted: August 10, 2016 Published: August 23, 2016 ABSTRACT Effective delivery of nanomedicines to tumor tissues depends on both the tumor microenvironment and nanomedicine properties. Accordingly, tumor microenvironment modification or advanced design of nanomedicine was emerging to improve nanomedicine delivery to tumors. However, few studies have emphasized the necessity to optimize the tumor microenvironment and nanomedicine properties simultaneously to improve tumor treatment. In the present study, imatinib mesylate (IMA) was used to normalize the tumor microenvironment including platelet-derived growth factor receptor-β expression inhibition, tumor vessel normalization, and tumor perfusion improvement as demonstrated by immunofluorescence staining. In addition, the effect of tumor microenvironment normalization on tumor delivery of nanomedicines with different sizes was carefully investigated. It was shown that IMA treatment significantly reduced the accumulation of nanoparticles (NPs) around 110 nm but enhanced the accumulation of micelles around 23 nm by in vivo fluorescence imaging experiment. Furthermore, IMA treatment limited the distribution of NPs inside tumors but increased that of micelles with a more homogeneous pattern. Finally, the anti-tumor efficacy study displayed that IMA pretreatment could significantly increase the therapeutic effects of paclitaxel-loaded micelles. All-together, a new strategy to improve nanomedicine delivery to tumor was provided by optimizing both nanomedicine size and the tumor microenvironment simultaneously, and it will have great potential in clinics for tumor treatment.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Imatinib inhibits VEGF-independent angiogenesis and improves delivery of nanoparticles to the tumor site in A459 xenograft lung carcinoma models.
“Another TKI, Imatinib, inhibits VEGF-independent angiogenesis and also improves the delivery of nanoparticles to the tumor site, which was observed in A459 xenograft tumor models (lung carcinoma) [28].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [28]
The Results and Discussion (page unavailable) report that imatinib improved delivery of 23-nm micelles to A549 lung-tumor xenografts, but reduced tumor accumulation of 110-nm nanoparticles. The paper reports PDGFR-β inhibition and vessel normalization, not inhibition of VEGF-independent angiogenesis. The citing sentence also prints the model as A459 rather than A549. (LLM, conf=0.89)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · see citing works
Fang, J. Q., Nakamura, H., & Maeda, H. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,573 · see citing works
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,196 · see citing works
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429 · see citing works
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · see citing works
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Perrault, S. D., Walkey, C., Jennings, T. L., Fischer, H. C., & Chan, W. C. W. (2009) · Nano Letters · doi:10.1021/nl900031y · Cited by 1,516 · see citing works
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · see citing works
Chauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101 · see citing works
Multistage nanoparticle delivery system for deep penetration into tumor tissue
Wong, C., Stylianopoulos, T., Cui, J., Martin, J. D., Chauhan, V. P., Jiang, W., Popović, Z., Jain, R. K., Bawendi, M. G., & Fukumura, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018382108 · Cited by 1,067 · see citing works
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · see citing works
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834 · see citing works
Strategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 815 · see citing works
Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · see citing works
Investigating the optimal size of anticancer nanomedicine
Tang, L., Yang, X., Yin, Q., Cai, K., Wang, H., Chaudhury, I., Yao, C., Zhou, Q., Kwon, M., Hartman, J. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411499111 · Cited by 658 · see citing works
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508 · see citing works
Wood, S. L., Pernemalm, M., Crosbie, P. A. J., & Whetton, A. D. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.001 · Cited by 487 · see citing works
Chauhan, V. P., Popović, Z., Chen, O., Cui, J., Fukumura, D., Bawendi, M. G., & Jain, R. K. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201104449 · Cited by 474 · see citing works
Pietras, K., Östman, A., SJÖQUIST, M., Buchdunger, E., Reed, R. K., Heldin, C., & Rubin, K. (2001) · PubMed · Cited by 449 · see citing works
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras, K., Rubin, K., Sjöblom, T., Buchdunger, E., Sjöquist, M., Heldin, C., & Östman, A. (2002) · PubMed · Cited by 432 · see citing works
wei, Z., Hao, J., Yuan, S., Li, Y., Juan, W., Sha, X., & Fang, X. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.030 · Cited by 426 · see citing works
Tumor Vessel Normalization by Chloroquine Independent of Autophagy
Maes, H., Kuchnio, A., Peric, A., Moens, S., Nys, K., Bock, K. D., Quaegebeur, A., Schoors, S., Γεωργιάδου, Μ., Wouters, J., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.025 · Cited by 411 · see citing works
Zhu, L., Wang, T., Perche, F., Taigind, A., & Torchilin, V. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304987110 · Cited by 360 · see citing works
A Nanoparticle Size Series for In Vivo Fluorescence Imaging
Popović, Z., Liu, W., Chauhan, V. P., Lee, J., Wong, C., Greytak, A. B., Insin, N., Nocera, D. G., Fukumura, D., Jain, R. K., et al. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201003142 · Cited by 332 · see citing works
Han, S., Li, Z., Zhu, J., Han, K., Zeng, Z., Hong, W., Li, W., Jia, H.-Z., Liu, Y., Zhuo, R., et al. (2015) · Small · doi:10.1002/smll.201402865 · Cited by 269 · see citing works
Preparation and brain delivery property of biodegradable polymersomes conjugated with ox26
Pang, Z., Lu, W., Gao, H., Hu, K., Chen, J., Zhang, C., Gao, X., Jiang, X., & Zhu, C. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.03.007 · Cited by 264 · see citing works
Self-citationPhotoswitchable nanoparticles for in vivo cancer chemotherapy
Tong, R., Chiang, H. H., & Kohane, D. S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315336110 · Cited by 227 · see citing works
LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma
Zhang, B., Sun, X., Mei, H., Wang, Y., Liao, Z., Chen, J., Zhang, Q., Hu, Y., Pang, Z., & Jiang, X. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.039 · Cited by 225 · see citing works
Self-citationHuang, S., Shao, K., Liu, Y., Kuang, Y., Li, J., An, S., Guo, Y., Ma, H., & Jiang, C. (2013) · ACS Nano · doi:10.1021/nn400548g · Cited by 213 · see citing works
Peptide Targeted Lipid Nanoparticles for Anticancer Drug Delivery
Pearce, T. R., Shroff, K., & Kokkoli, E. (2012) · Advanced Materials · doi:10.1002/adma.201200832 · Cited by 195 · see citing works
Guo, S., Lin, C. M., Xu, Z., Miao, L., Wang, Y., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn5010815 · Cited by 164 · see citing works
Schädlich, A., Caysa, H., Mueller, T., Tenambergen, F., Rose, C., Göpferich, A. M., Kuntsche, J., & Mäder, K. (2011) · ACS Nano · doi:10.1021/nn2026353 · Cited by 161 · see citing works
Hwang, R. F., Yokoi, K., Bucana, C. D., Tsan, R. Z., Killion, J. J., Evans, D. B., & Fidler, I. J. (2003) · PubMed · Cited by 158 · see citing works
Yang, Y. L., Zhang, X., & Qiu, L. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.096 · Cited by 132 · see citing works
Chakroborty, D., Sarkar, C., Yu, H., Wang, J., Liu, Z., Dasgupta, P., & Basu, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108696108 · Cited by 119 · see citing works
Huile, G., Pan, S., Yang, Z. H., Cao, S., Chen, C., Xin-guo, J., Shun, S., Zhiqing, P., & Yu, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.069 · Cited by 115 · see citing works
Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery
Tailor, T. D., Hanna, G., Yarmolenko, P., Dreher, M. R., Warner, A. B., Nixon, A. B., Spasojević, I., & Dewhirst, M. W. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0856 · Cited by 106 · see citing works
Kitadai, Y., Sasaki, T., Kuwai, T., Nakamura, T., Bucana, C. D., & Fidler, I. J. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060653 · Cited by 104 · see citing works
Targeting fibronectins of glioma extracellular matrix by CLT1 peptide-conjugated nanoparticles
Zhang, B., Shen, S., Liao, Z., Shi, W., Wang, Y., Zhao, J., Hu, Y., Yang, J., Chen, J., Mei, H., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.01.046 · Cited by 101 · see citing works
Self-citationCREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery
Zhao, J., Zhang, B., Shen, S., Chen, J., Zhang, Q., Jiang, X., & Pang, Z. (2015) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2015.03.019 · Cited by 96 · see citing works
Self-citationImatinib disrupts lymphoma angiogenesis by targeting vascular pericytes
Ruan, J., Luo, M., Wang, C., Fan, L., Yang, S. N., Cárdenas, M., Geng, H., Leonard, J. P., Melnick, A. M., Cerchietti, L. C. A., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490763 · Cited by 94 · see citing works
The role of fibrin in tumor metastasis
Costantini, V., & Zacharski, L. R. (1992) · Cancer and Metastasis Reviews · doi:10.1007/bf01307183 · Cited by 89 · see citing works
Fan, Y., Du, W., He, B., Fu, F.-Y., Yuan, L., Wu, H., Dai, W., Zhang, H., Wang, X., Wang, J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.012 · Cited by 79 · see citing works
Jin, S., Ma, X., Ma, H., Zheng, K., Liu, J., Hou, S., Meng, J., Wang, P. C., Wu, X., & Liang, X. (2012) · Nanoscale · doi:10.1039/c2nr31877f · Cited by 75 · see citing works
Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity
Napier, R. J., Norris, B. A., Swimm, A. I., Giver, C. R., Harris, W. A. C., Laval, J., Napier, B. A., Patel, G., Crump, R., Peng, Z., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1004770 · Cited by 72 · see citing works
A Nanoparticle Size Series for In Vivo Fluorescence Imaging
Popović, Z., Liu, W., Chauhan, V. P., Lee, J., Wong, C., Greytak, A. B., Insin, N., Nocera, D. G., Fukumura, D., Jain, R. K., et al. (2010) · Angewandte Chemie · doi:10.1002/ange.201003142 · Cited by 69 · see citing works
Olson, P., & Hanahan, D. (2009) · Science · doi:10.1126/science.1175940 · Cited by 62 · see citing works
Falcón, B. L., Pietras, K., Chou, J., Chen, D., Sennino, B., Hanahan, D., & McDonald, D. M. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.02.019 · Cited by 53 · see citing works
A tissue factor targeted nanomedical system for thrombi-specific drug delivery
Shi, W., Mei, H., Deng, J., Chen, C., Wang, H., Guo, T., Zhang, B., Li, L., Pang, Z., Jiang, X., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.094 · Cited by 32 · see citing works
Self-citationWei, Y., Xu, S., Wang, F., Zou, A., Zhang, S., Xiong, Y., Cao, S., Zhang, Q., Wang, Y., & Jiang, X. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24234 · Cited by 30 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,435 · see citing works
Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13092053 · Cited by 468 · see citing works
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330 · see citing works
Self-citationNanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Yang, S., & Gao, H. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.004 · Cited by 256 · see citing works
Hyperthermia and smart drug delivery systems for solid tumor therapy
Seynhaeve, A. L. B., Amin, M., Haemmerich, D., van Rhoon, G. C., & ten Hagen, T. L. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.004 · Cited by 235 · see citing works
Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope
Salvioni, L., Rizzuto, M. A., Bertolini, J. A., Pandolfi, L., Colombo, M., & Prosperi, D. (2019) · Cancers · doi:10.3390/cancers11121855 · Cited by 200 · see citing works
Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152 · see citing works
Self-citationDelivery of Nanoparticle-Based Radiosensitizers for Radiotherapy Applications
Boateng, F., & Ngwa, W. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010273 · Cited by 115 · see citing works
Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy
Zhu, Y., Yu, X., Thamphiwatana, S., Zheng, Y., & Pang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.010 · Cited by 116 · see citing works
Self-citationNanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology
Hristova‐Panusheva, K., Xenodochidis, C., Georgieva, M., & Krasteva, N. A. (2024) · Pharmaceuticals · doi:10.3390/ph17060677 · Cited by 105 · see citing works
Amin, M., Huang, W., Seynhaeve, A. L. B., & ten Hagen, T. L. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111007 · Cited by 99 · see citing works
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98 · see citing works
“Another TKI, Imatinib, inhibits VEGF-independent angiogenesis and also improves the delivery of nanoparticles to the tumor site, which was observed in A459 xenograft tumor models (lung carcinoma) [28].”
BackgroundXiao, W., Ruan, S., Yu, W., Wang, R., Hu, C., Liu, R., & Gao, H. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00475 · Cited by 84 · see citing works
Low, L. E., Wu, J., Lee, J., Tey, B. T., Goh, B. H., Gao, J., Li, F., & Ling, D. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.014 · Cited by 67 · see citing works
Nano-targeting vascular remodeling in cancer: Recent developments and future directions
Giordo, R., Wehbe, Z., Paliogiannis, P., Eid, A. H., Mangoni, A. A., & Pintus, G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.001 · Cited by 66 · see citing works
Nanoparticle Delivery and Tumor Vascular Normalization: The Chicken or The Egg?
Mattheolabakis, G., & Mikelis, C. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01227 · Cited by 63 · see citing works
Polymeric Micelles in Cancer Immunotherapy
Wan, Z., Zheng, R., Moharil, P., Liu, Y., Chen, J., Sun, R., Song, X., & Ao, Q. (2021) · Molecules · doi:10.3390/molecules26051220 · Cited by 52 · see citing works
Zhang, B., Jin, K., Jiang, T., Wang, L., Shen, S., Luo, Z., Tuo, Y., Liu, X., Hu, Y., & Pang, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-09520-7 · Cited by 49 · see citing works
Self-citationWang, R., Xu, X., Li, D., Zhang, W., Shi, X., Xu, H., Hong, J., Yao, S., Liu, J., Wei, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121737 · Cited by 48 · see citing works
Zhang, B., Jiang, T., Tuo, Y., Jin, K., Luo, Z., Shi, W., Mei, H., Hu, Y., Pang, Z., & Jiang, X. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.007 · Cited by 41 · see citing works
Self-citationLan, H., We, Z., Jin, K., Liu, Y., & Wang, Z. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1809559 · Cited by 34 · see citing works
Guanidine-modified nanoparticles as robust BTZ delivery carriers and activators of immune responses
Xu, X., Wang, R., Li, D., Xiang, J., Zhang, W. J., Shi, X., Xu, H., Yao, S., Liu, J., Shao, S., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.004 · Cited by 23 · see citing works
Nanoparticles for tumor targeting
Jiang, T., Jin, K., Liu, X., & Pang, Z. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-101914-6.00008-9 · Cited by 22 · see citing works
Self-citationLai, Y., Chiang, C., Kao, T.-H., & Chen, S.-Y. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s161314 · Cited by 19 · see citing works
Modulation of Tumor Vasculature Network: Key Strategies
Taleb, M., Mohammadkhani, N., Bahreini, F., Ovais, M., & Nie, G. (2022) · Small Structures · doi:10.1002/sstr.202100164 · Cited by 16 · see citing works
Nanotechnology as a Delivery Tool for Precision Cancer Therapies
Sharma, B., Crist, R. M., & Adiseshaiah, P. P. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0152-y · Cited by 16 · see citing works
Parallel model exploration for tumor treatment simulations
Akasiadis, C., Ponce-de-León, M., Montagud, A., Michelioudakis, E., Atsidakou, A., Alevizos, E., Artikis, A., Valencia, A., & Παλιούρας, Γ. (2022) · Computational Intelligence · doi:10.1111/coin.12515 · Cited by 14 · see citing works
Shaikh, S., Chary, P. S., & Mehra, N. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01527 · Cited by 13 · see citing works
Al‐Dhubiab, B. E., Almuqbil, R. M., & Nair, A. B. (2025) · Pharmaceuticals · doi:10.3390/ph18050746 · Cited by 10 · see citing works
Emerging Trends in the Application of Nanosuspension-Based Biomaterials for Anticancer Drug Delivery
Aldeeb, M. M. E., Wilar, G., Suhandi, C., Mohammed, A. F. A., Mahmoud, S. A., Elamin, K. M., & Wathoni, N. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s513030 · Cited by 9 · see citing works
Zhao, C., Wang, W., Huang, Z., Wan, Y., Xu, R., Zhang, J., Zhao, B., Wang, K., Wen, S., Zhong, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.08.001 · Cited by 9 · see citing works
Ishizawa, K., Togami, K., Tada, H., & Chono, S. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.08.028 · Cited by 9 · see citing works
Responsive Polymeric Nanotherapeutics
Pamfil, D., & Vasile, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813932-5.00002-9 · Cited by 7 · see citing works
Sandha, K. K., Behera, C., Chibber, P., Kumar, R., Kumar, A., Mondhe, D. M., Singh, G., & Gupta, P. N. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01081 · Cited by 6 · see citing works
Tian, Y., Yan, W., Wei, L., & Ho, D. L. (2019) · IEEE Access · doi:10.1109/access.2019.2896640 · Cited by 6 · see citing works
Haze, H., Sier, C. F. M., Vahrmeijer, A. L., & Vuijk, F. A. (2024) · Surgeries · doi:10.3390/surgeries5010007 · Cited by 5 · see citing works
Zhang, B., Wang, H., Jin, K., Jiang, T., Shen, S., Luo, Z., Tuo, Y., Jiang, X., Liu, X., Hu, Y., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.017 · Cited by 5 · see citing works
Self-citationAlmeida, J. C., Helal‐Neto, E., Pinto, S. R., dos Santos, S. N., Bernardes, E. S., Al-Qahtani, M. H., Nigro, F., Alencar, L. M. R., Ricci‐Júnior, E., & Santos‐Oliveira, R. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190816235147 · Cited by 4 · see citing works
Askenase, P. W. (2020) · Preprints.org · doi:10.20944/preprints202006.0200.v1 · Cited by 2 · see citing works
A Review on Targeted Drug Delivery System - Nanoparticles
Nathani, S. (2016) · Research and reviews : journal of pharmaceutics and nanotechnology
- Authors
- Zhang, B., Shi, W., Jiang, T., Wang, L., Mei, H., Lu, H., Hu, Y., & Pang, Z.
- Affiliations
- Wuhan Union Hospital (CN)
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Corresponding author
- Zhang, Bo
- Shi, Wei
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-08-23
- Volume
- 7
- Issue
- 38
- Pages
- 62607-62618
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC5308750
- OpenAlex
- W2518611253
- Cited by
- 41
- References
- 49
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 6 · 2018: 1 · 2017: 9 · 2016: 2
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81370622, 81472757, 81302043)
- Ministry of Education of the People's Republic of China (20100071120050)
- Fudan University
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- tumor microenvironment, nanomedicine delivery, imatinib mesylate, tumor vasculature normalization, tumor perfusion, nanoparticle size, micelles, tumor targeting, cancer therapy, drug delivery to tumors, tumor hypoxia, tumor stroma remodeling
- MeSH terms
- Imatinib Mesylate, A549 Cells, Animals, Antineoplastic Agents, Drug Screening Assays, Antitumor, Humans, Male, Mice, Inbred BALB C, Mice, Nude, Micelles, Microscopy, Fluorescence, Neoplasm Transplantation, Neovascularization, Pathologic, Perfusion, Drug Delivery Systems, Paclitaxel, Receptor, Platelet-Derived Growth Factor beta, Cell Line, Tumor, Nanomedicine, Mice, Nanoparticles, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
